Stockreport

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment [Yahoo! Finance]

BioCryst Pharmaceuticals, Inc.  (BCRX) 
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: biocryst.gcs-web.com/investor-relations
PDF RESEARCH TRIANGLE PARK, N.C., June 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence showing that patie [Read more]